0001209191-20-045105.txt : 20200805
0001209191-20-045105.hdr.sgml : 20200805
20200805162422
ACCESSION NUMBER: 0001209191-20-045105
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200803
FILED AS OF DATE: 20200805
DATE AS OF CHANGE: 20200805
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Silva Paul M
CENTRAL INDEX KEY: 0001446372
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 201077689
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY ST
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-08-03
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001446372
Silva Paul M
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
SVP & Controller
Common Stock
2020-08-03
4
M
0
809
86.52
A
15741
D
Common Stock
2020-08-03
4
S
0
51
276.00
D
15690
D
Common Stock
2020-08-03
4
S
0
310
277.73
D
15380
D
Common Stock
2020-08-03
4
S
0
429
278.92
D
14951
D
Common Stock
2020-08-03
4
S
0
19
279.61
D
14932
D
Common Stock
169
I
401(k)
Stock Option (Right to Buy)
86.52
2020-08-03
4
M
0
809
0.00
D
2027-02-02
Common Stock
809
1618
D
Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $277.73 (range $277.25 to $278.22).
Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $278.92 (range $278.47 to $279.38).
The option vests in 16 quarterly installments from 02/03/2017.
/s/ Sabrina Yohai, Attorney-in-Fact
2020-08-05